Efficacy and safety of eribulin in various subtypes of breast cancer: data from real clinical practice in Russia
https://doi.org/10.18027/2224-5057-2017-3-46-56
Abstract
The article presents a pooled experience of the use of eribulin in the real clinical practice of treatment of metastatic breast cancer in Russian oncological institutions. The effectiveness of the drug in monotherapy with HER2‑negative breast cancer was analyzed, groups of patients with most effective use of eribulin were identified depending on the localization of metastases, the most effective lines of therapy. The effectiveness of the drug in combination with trastuzumab in HER2‑positive breast cancer is described, as well as toxic reactions.
About the Authors
L. V. Manzyuk
N. N. Blokhin Russian Cancer Research Center
Russian Federation
Professor, Leading Researcher of the Outpatient Chemotherapy Department
Russian Federation
Professor, Leading Researcher of the Outpatient Chemotherapy Department
E. I. Kovalenko
N. N. Blokhin Russian Cancer Research Center
Russian Federation
PhD, Researcher of the Outpatient Сhemotherapy Department
Russian Federation
PhD, Researcher of the Outpatient Сhemotherapy Department
V. A. Gorbunova
N. N. Blokhin Russian Cancer Research Center
Russian Federation
Professor, Leading Researcher of the Chemotherapy Department
Competing Interests: д. м. н., профессор, в. н. с. отделения химиотерапии
Russian Federation
Professor, Leading Researcher of the Chemotherapy Department
Competing Interests: д. м. н., профессор, в. н. с. отделения химиотерапии
L. V. Bolotina
P. A. Herzen Moscow Research Institute of Oncology of National Medical Research Radiological Centre
Russian Federation
PhD, Head of the Сhemotherapy Department
Russian Federation
PhD, Head of the Сhemotherapy Department
T. Y. Semiglazova
N. N. Petrov Russian Cancer Research Center
Russian Federation
Professor, Head of the Scientific Department of Innovative Methods of Therapeutic Oncology and Rehabilitation
Russian Federation
Professor, Head of the Scientific Department of Innovative Methods of Therapeutic Oncology and Rehabilitation
L. A. Zhilyaeva
Kursk Regional Clinical Oncology Center
Russian Federation
Head of the Chemotherapy Department
Russian Federation
Head of the Chemotherapy Department
Y. A. Mishina
Kursk Regional Clinical Oncology Center
Russian Federation
MD
Russian Federation
MD
D. M. Ponomarenko
Irkutsk Regional Clinical Oncology Center
Russian Federation
PhD, Head of the Chemotherapy Department
Russian Federation
PhD, Head of the Chemotherapy Department
V. E. Goldberg
Tomsk Oncology National Research Medical Center
Russian Federation
Professor, Head of the Chemotherapy Department
Russian Federation
Professor, Head of the Chemotherapy Department
N. O. Popova
Tomsk Oncology National Research Medical Center
Russian Federation
PhD, Senior Researcher
Russian Federation
PhD, Senior Researcher
E. V. Karabina
Tula Regional Clinical Oncology Center
Russian Federation
Head of the Chemotherapy Department
Russian Federation
Head of the Chemotherapy Department
G. Z. Mukhametshina
Tatarstan Regional Clinical Oncology Center
Russian Federation
PhD, Head of the Department of Chemotherapy No.1
Russian Federation
PhD, Head of the Department of Chemotherapy No.1
A. I. Khasanova
Tatarstan Regional Clinical Oncology Center
Russian Federation
PhD, Head of the Department of Chemotherapy No. 2
Russian Federation
PhD, Head of the Department of Chemotherapy No. 2
S. Z. Safina
Tatarstan Regional Clinical Oncology Center
Russian Federation
PhD, Head of the Department of Chemotherapy No.3
Russian Federation
PhD, Head of the Department of Chemotherapy No.3
M. V. Shaidorov
Tolyatti State Clinical Hospital No. 5
Russian Federation
PhD, Head of the Chemotherapy Department
Russian Federation
PhD, Head of the Chemotherapy Department
L. Y. Vladimirova
Rostov Research Oncology Institute
Russian Federation
Professor, Head of the Department of Antitumor Drug Therapy No.1
Russian Federation
Professor, Head of the Department of Antitumor Drug Therapy No.1
I. S. Mitashok
Rostov Research Oncology Institute
Russian Federation
Head of the Department of Antitumor Drug Therapy No. 2
Russian Federation
Head of the Department of Antitumor Drug Therapy No. 2
E. P. Prokofieva
Penza Regional Clinical Oncology Center
Russian Federation
Head of the Chemotherapy Department of the Day Hospital
Russian Federation
Head of the Chemotherapy Department of the Day Hospital
I. V. Evstigneeva
Tver Regional Clinical Oncology Center,
Russian Federation
Head of the Dispensary Department
Russian Federation
Head of the Dispensary Department
I. I. Andreyashkina
Saratov Regional Oncological Center No. 2
Russian Federation
PhD, Head of the Department of Chemotherapy
Russian Federation
PhD, Head of the Department of Chemotherapy
N. A. Abramova
Rostov Research Oncology Institute
Russian Federation
MD of the Department of Antitumor Drug Therapy No.1
Russian Federation
MD of the Department of Antitumor Drug Therapy No.1
I. L. Popova
Rostov Research Oncology Institute
Russian Federation
MD of the Department of Antitumor Drug Therapy No.1
Russian Federation
MD of the Department of Antitumor Drug Therapy No.1
A. A. Teterich
Belgorod Regional Clinical Oncology Center
Russian Federation
Head of department
Russian Federation
Head of department
E A. Gaisina
Tyumen Medical Center «Medical City»
Russian Federation
PhD, Head of the Chemotherapy Department
Russian Federation
PhD, Head of the Chemotherapy Department
V. A. Chubenko
St. Petersburg Clinical Scientific and Practical Center of Specialized Medical (Oncological)
Russian Federation
PhD, Head of the Chemotherapy Department
Russian Federation
PhD, Head of the Chemotherapy Department
S. V. Limareva
N. N. Blokhin Russian Cancer Research Center
Russian Federation
PhD, Scientific Researcher of the Chemotherapy Department
Russian Federation
PhD, Scientific Researcher of the Chemotherapy Department
N. M. Tikhanovskaya
Rostov Research Oncology Institute
Russian Federation
MD of the Department of Antitumor Drug Therapy No.1
Russian Federation
MD of the Department of Antitumor Drug Therapy No.1
A. E. Storozhakova
Rostov Research Oncology Institute
Russian Federation
MD of the Department of Antitumor Drug Therapy No.1
Russian Federation
MD of the Department of Antitumor Drug Therapy No.1
N. Y. Samaneva
Rostov Research Oncology Institute
Russian Federation
MD of the Department No.2 of Antitumor Drug Therapy
Russian Federation
MD of the Department No.2 of Antitumor Drug Therapy
Y. V. Svetitskaya
Rostov Research Oncology Institute
Russian Federation
MD of the Department No.2 of Antitumor Drug Therapy
Russian Federation
MD of the Department No.2 of Antitumor Drug Therapy
T. A. Snezhko
Rostov Research Oncology Institute
Russian Federation
MD of the Department No.2 of Antitumor Drug Therapy
Russian Federation
MD of the Department No.2 of Antitumor Drug Therapy
E. A. Kalabanova
Rostov Research Oncology Institute
Russian Federation
MD of the Department No.2 of Antitumor Drug Therapy
Russian Federation
MD of the Department No.2 of Antitumor Drug Therapy
A. Y. Povyshev
Khanty-Mansiysk Autonomous Okrug of Ugra «District Clinical Hospital»
Russian Federation
MD
Russian Federation
MD
I. V. Yudina
Omsk Regional Clinical Oncology Center
Russian Federation
Head of department
Russian Federation
Head of department
L. V. Vorotilina
Omsk Regional Clinical Oncology Center
Russian Federation
MD
Russian Federation
MD
T. V. Andreeva
Smolensk Regional Clinical Oncology Center
Russian Federation
Head of the Chemotherapy Department
Russian Federation
Head of the Chemotherapy Department
G. C. Tumanyan
Primorsky Regional Clinical Oncology Center
Russian Federation
MD
Russian Federation
MD
A. E. Kozyakov
Novosibirsk Regional Clinical Oncology Center
Russian Federation
Head of the Oncology Department No. 2
Russian Federation
Head of the Oncology Department No. 2
L. A. Gilmutdinova
Khabarovsk Regional Clinical Oncology Center
Russian Federation
Head of department
Russian Federation
Head of department
References
1. Cardoso F., Harbeck N., Fallowfield L., Kyriakides S., Senkus E. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 2012, Vol. 23, pp. vii11–vii19.
2. Cortes J., O’Shaughnessy J., Loesch D. et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study, Lancet, 2011, Vol. 377, pp. 914–923.
3. Kaufman P. A., Awada A., Twelves C. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane, J. Clin. Oncol., 2015, Vol. 33, pp. 594–601.
4. Twelves C., Awada A., Cortes J., Yelle I., Velikova G., Olivo M., Song J., Dutcus C., Kaufman P. Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer, Breast Cancer: Basic and Clinical Research, 2016, Vol. 10, pp 77–84.
5. Twelves C., Cortes J., Vandat L. et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res. Treat., 2014, Vol. 148, pp. 553–561.
6. Pivot X., Marm F., Koenigsberg R., Guo M., Berrak E., Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy, Annals of Oncology, 2016, Vol. 27, pp. 1525–1531.
7. Wilks Sh., Puhalla Sh., O’Shaughnessy J. et al. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer, Clin. Breast Cancer, 2014, Vol. 14, No. 6, pp. 405–412.
8. Инструкция по медицинскому применению препарата Халавен® (РУ ЛП-001782 от 28.07.2012, с изменениями от 08.02.2017). [Instructions for the medical use of the drug Halaven® (RU LP-001782 dated 28.07.2012, as amended on 08.02.2017) (In Russ.)]
9. Blum J. L., Twelves C. J., Dutcus C. et al. Impact of the number of prior chemotherapy regimens on overall survival (OS) among subjects with locally recurrent or MBC treated with eribulin mesylate: results from the Phase III EMBRACE study. Presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), December 8–12, 2010, San Antonio, TX, USA, P6-13–01.
10. Towle M. J., Salvato K. A., Wels B. F. et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions, Cancer Res., 2011, Vol. 71. No. 2. pp. 496–505.
11. Funahashi Y., Okamoto K., Adachi Y. et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models, Cancer Sci., 2014, Vol. 105. No. 10. pp. 1334–1342.
12. Ueda S., Saeki T., Takeuchi H. et al. In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients a comparison to bevacizumab, Br. J. Cancer, 2016, Vol. 114, pp. 1212–1218.
13. Yoshida T., Ozawa Y., Kimura T. et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial – mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states, Br. J. Cancer, 2014, Vol. 110, pp. 1497–505.
Review
For citations:
Manzyuk L.V., Kovalenko E.I., Gorbunova V.A., Bolotina L.V., Semiglazova T.Y., Zhilyaeva L.A., Mishina Y.A., Ponomarenko D.M., Goldberg V.E., Popova N.O., Karabina E.V., Mukhametshina G.Z., Khasanova A.I., Safina S.Z., Shaidorov M.V., Vladimirova L.Y., Mitashok I.S., Prokofieva E.P., Evstigneeva I.V., Andreyashkina I.I., Abramova N.A., Popova I.L., Teterich A.A., Gaisina E.A., Chubenko V.A., Limareva S.V., Tikhanovskaya N.M., Storozhakova A.E., Samaneva N.Y., Svetitskaya Y.V., Snezhko T.A., Kalabanova E.A., Povyshev A.Y., Yudina I.V., Vorotilina L.V., Andreeva T.V., Tumanyan G.C., Kozyakov A.E., Gilmutdinova L.A. Efficacy and safety of eribulin in various subtypes of breast cancer: data from real clinical practice in Russia. Malignant tumours. 2017;(3):46-56. (In Russ.) https://doi.org/10.18027/2224-5057-2017-3-46-56
Views:
1192
Email this article 